Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial

OBJECTIVES: Pharmacokinetics studies recommend increasing efavirenz dosage in tuberculosis/HIV patients using rifampicin. We aimed to evaluate efficacy and safety of 600 versus 800 mg of efavirenz in tuberculosis/HIV patients using rifampicin. DESIGN: We conducted an open label, multicentre, randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xavier, Mariana S., Trajman, Anete, Schmaltz, Carolina A. S., Sant'anna, Flavia M., Maia, Ivan R., Hadad, David J., do Brasil, Pedro Emmanuel A. A., Rolla, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354140/
https://www.ncbi.nlm.nih.gov/pubmed/30792988
http://dx.doi.org/10.1155/2018/9231835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354140/
https://www.ncbi.nlm.nih.gov/pubmed/30792988
http://dx.doi.org/10.1155/2018/9231835

Ejemplares similares